Glucocorticoid-induced osteoporosis and parathyroid hormone.

R. Carpinteri, T. Porcelli, C. Mejia, I. Patelli, J. P. Bilezikian, E. Canalis, A. Angeli, A. Giustina, G. Mazziotti

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)

Abstract

Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Bisphosphonates are considered the first-line treatment option for the majority of glucocorticoid-treated patients at increased risk of fractures. However, the anti-resorptive mechanism of bisphosphonates does not address the major pathophysiological mechanisms of impaired bone formation during chronic glucocorticoid treatment. PTH, when administered intermittently and at low doses, has effects on bone formation opposite to those of glucocorticoids and therefore is conceptually a more attractive approach. Teriparatide (1-34PTH) has been studied in patients with GIO with effects on bone mineral density and on fracture risk which were shown to be superior to those obtained with alendronate.

Original languageEnglish
Pages (from-to)16-21
Number of pages6
JournalJournal of Endocrinological Investigation
Volume33
Issue number7 Suppl
Publication statusPublished - 2010

Funding

FundersFunder number
National Institute of Diabetes and Digestive and Kidney DiseasesR01DK032333

    ASJC Scopus Subject Areas

    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Fingerprint

    Dive into the research topics of 'Glucocorticoid-induced osteoporosis and parathyroid hormone.'. Together they form a unique fingerprint.

    Cite this

    Carpinteri, R., Porcelli, T., Mejia, C., Patelli, I., Bilezikian, J. P., Canalis, E., Angeli, A., Giustina, A., & Mazziotti, G. (2010). Glucocorticoid-induced osteoporosis and parathyroid hormone. Journal of Endocrinological Investigation, 33(7 Suppl), 16-21.